The story of MedDay began in 2011, when Frédéric Sedel, MD, PhD, a neurologist and neuroscientist met with Guillaume Brion, an entrepreneur with experience in drug development. Both used their expertise and worked together to create MedDay, a pioneering biopharmaceutical company with a unique approach focusing on neurometabolism.
Alongside its main program in Progressive Multiple Sclerosis, MedDay has laid the foundation to become the global leader in the neurometabolic field by investing in SPECMET, its innovative discovery platform. SPECMET will allow MedDay to embark on a more ambitious quest to find therapies for important neurological diseases with metabolic abnormalities.
MedDay has a new and unique perspective: exploring metabolic pathways in people affected by nervous systems disorders in order to develop our growing pipeline of promising neurometabolic programs.
Company inception – Founded by Dr. Frédéric Sedel and Dr. Guillaume Brion
Series A financing €8 million
1st patent granted in the US and in EU
Series B financing €34 million
Acquisition of the company “Profilomic SA” to strengthen SPECMET, MedDay’s metabolomics research platform
Christian Chavy appointed as MedDay's new Chief Executive Officer